Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK-Reference-Cited by-同舟云学术

Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK

Published:2010-12 Issue:3 Volume:43 Page:251-259
ISSN:1473-0502
Container-title:Transfusion and Apheresis Science
language:en
Short-container-title:Transfusion and Apheresis Science

Author:

van Eerd Margreet C.,Mario Ouwens J.N.,de Peuter Maria A.

Publisher

Elsevier BV

Subject

Hematology

Reference31 articles.

1. Update on pathogen reduction technology for therapeutic plasma: an overview;Solheim;Transfus Apher Sci,2006

2. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma;Riedler;Vox Sang,2003

3. Pathogen reduction of blood components;Solheim;Transfus Apher Sci,2008

4. Introduction of OctaplasLG® in clinical use decreased the rate of severe adverse reactions;Krusius;Vox Sang,2009

5. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma octaplasLG®;Neisser-Svae;Vox Sang,2009

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia;Blood Advances;2024-05-31

2. Cost‐effectiveness of sutimlimab in cold agglutinin disease;American Journal of Hematology;2024-05-11

3. Thirty years of experience with solvent/detergent‐treated plasma for transfusion medicine;Transfusion;2024-04-21

4. A cost‐effectiveness analysis of lusutrombopag for thrombocytopenia in patients with chronic liver disease in Japan;JGH Open;2021-06-26